CAC 40
8 058,13 -7,02 (-0,09 %) Euro Stoxx 50
4 962,95 -18,14 (-0,36 %) Dow Jones
38 386,09 +146,43 (+0,38 %) EUR/USD
1,0727 +0,0002 (+0,02 %) Gold future
2 327,10 -30,60 (-1,30 %) Bitcoin EUR
58 726,11 -631,68 (-1,06 %)
Orion Oyj (0M2O.IL)
Orion Oyj
Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 3 657
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Liisa Hurme | Pres, CEO & Chairman of Exec. Management Board | 106,13k | S.O. | 1967 |
| Mr. Jari Karlson M.Sc., M.Sc. (Econ.) | CFO & Member of the Exec. Management Board | S.O. | S.O. | 1961 |
| Mr. Olli Huotari Ll.M. | Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board | S.O. | S.O. | 1966 |
| Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) | Sr. VP of Generics and Consumer Health Bus. Division & Member of the Exe. Mgmt. Board | S.O. | S.O. | 1966 |
| Ms. Virve Laitinen M.Sc. (Tech.), MBA | Sr. VP of Corp. Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. Board | S.O. | S.O. | 1972 |
| Prof. Outi Vaarala M.D., Ph.D. | Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board | S.O. | S.O. | 1962 |
| Mr. Juhani Kankaanpaa | Sr. VP of Global Operations & Member of Exec. Management Board | S.O. | S.O. | S.O. |
| Mr. Niclas Lindstedt EMBA, M.Sc. | Sr. VP of Animal Health Bus. Division & Member of the Exe. Mgmt. Board | S.O. | S.O. | S.O. |
| Mr. Hao Pan M.Sc. | Sr. VP of the Branded Products Bus. Division & Member of the Exe. Mgmt. Board | S.O. | S.O. | 1971 |
| Mr. Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations & Financial Communications Officer | S.O. | S.O. | S.O. |
Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic and proprietary drugs, as well as provides contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. The company serves primarily healthcare services providers and professional, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Further, it has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. The company was founded in 1917 and is headquartered in Espoo, Finland.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Orion Oyj en date du 1 octobre 2023 est 3. Les scores principaux sont Audit : 4; Société : 2; Droits des actionnaires : 10; Compensation : 6.
